Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome

被引：0
|
作者：
Kibum Kim
Daniel R. Touchette
Larisa H. Cavallari
Amer K. Ardati
Robert J. DiDomenico
机构：
[1] University of Utah,Department of Pharmacotherapy and Pharmacotherapy Outcomes Research Center
[2] University of Illinois at Chicago,Center for Pharmacoepidemiology and Pharmacoeconomic Research
[3] University of Illinois at Chicago,Department of Pharmacy Systems, Outcomes and Policy
[4] University of Florida,Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics
[5] University of Illinois at Chicago,Division of Cardiology
[6] University of Illinois at Chicago,Department of Pharmacy Practice
来源：
Cardiovascular Drugs and Therapy | 2019年 / 33卷
关键词：
Acute coronary syndrome; Personalized medicine; Ticagrelor; Clopidogrel; P2Y; inhibitors; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：533 / 546
页数：13
相关论文
共 50 条
  • [41] What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?
    Cohen, Michael V.
    Downey, James M.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (02) : 121 - 130
  • [42] The impact of in-hospital P2Y12 inhibitor switch in patients with acute coronary syndrome
    Gajanana, Deepakraj
    Weintraub, William S.
    Kolm, Paul
    Rogers, Toby
    Iantorno, Micaela
    Buchanan, Kyle D.
    Ben-Dor, Itsik
    Pichard, Augusto D.
    Satler, Lowell F.
    Thourani, Vinod H.
    Torguson, Rebecca
    Okubagzi, Petros G.
    Waksman, Ron
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2018, 19 (08) : 912 - 916
  • [43] COST-EFFECTIVENESS OF TICAGRELOR IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Kim, K.
    Calabrese, M.
    Lin, F. J.
    Ojo, O.
    Cavallari, L. H.
    Touchette, D. R.
    VALUE IN HEALTH, 2013, 16 (03) : A284 - A284
  • [44] Impact of the type of acute coronary syndrome on the pharmocodynamic response to P2Y12 inhibitors in the acute and maintenance phase of therapy
    Lugo Gavidia, L.
    Vivas, D.
    De La Hera, J. M.
    Tello-Montoliu, A.
    Marcano, A. L.
    Besteiro, A.
    Silva, I.
    Gomez-Polo, J. C.
    Playan, J.
    Gomez-Hospital, J. A.
    Cequier, A.
    Marin, F.
    Roldan, I.
    Ferreiro, J. L.
    EUROPEAN HEART JOURNAL, 2019, 40 : 73 - 73
  • [45] Is Pretreatment With P2Y12 Inhibitors in Non-ST-Segment-Elevation Acute Coronary Syndrome Clinically Justified? Pretreatment With P2Y12 Inhibitors in Non-ST-Segment-Elevation Acute Coronary Syndrome Is Clinically Justified Response
    Collet, Jean-Philippe
    Silvain, Johanne
    Bellemain-Appaix, Anne
    Montalescot, Gilles
    CIRCULATION, 2014, 130 (21) : 1903 - 1903
  • [46] Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y12 Inhibitors in Patients With Acute Coronary Syndrome
    Flores-Blanco, Pedro J.
    Cambronero-Sanchez, Francisco
    Raposeiras-Roubin, Sergio
    Abu-Assi, Emad
    Leithold, Gunnar
    Cobas-Paz, Rafael
    Rodriguez Serrano, Ana I.
    CaIvo-Iglesias, Francisco
    Valdes, Mariano
    Januzzi, James L.
    Iniguez-Romo, Andres
    Manzano-Fernandez, Sergio
    REVISTA ESPANOLA DE CARDIOLOGIA, 2018, 71 (07): : 538 - 544
  • [47] Evaluation of cost-effectiveness of platelet reactivity analysis using the VerifyNow P2Y(12) assay in patients after acute coronary syndrome
    Rudakova, A. V.
    Lomakin, N. V.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2015, 11 (04) : 359 - 364
  • [48] Is Pretreatment With P2Y12 Inhibitors in Non-ST-Segment-Elevation Acute Coronary Syndrome Clinically Justified? Pretreatment with P2Y12 Inhibitors in Non-ST-Segment-Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy
    Collet, Jean-Philippe
    Silvain, Johanne
    Bellemain-Appaix, Anne
    Montalescot, Gilles
    CIRCULATION, 2014, 130 (21) : 1904 - 1914
  • [49] Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome Agents, indications, issues to consider in clinical practice
    Sibbing, D.
    Orban, M.
    Massberg, S.
    HAMOSTASEOLOGIE, 2013, 33 (01): : 9 - 15
  • [50] P2Y12 inhibitor in acute coronary syndromes
    Wiwanitkit, Viroj
    NATIONAL MEDICAL JOURNAL OF INDIA, 2013, 26 (04): : 249 - 249
12345